BACKGROUND: Acute coronary syndrome includes life-threatening clinical conditions
ranging from unstable angina to non-Q-wave myocardial infarction and Q-wave myocardial …

Purpose The recommended pharmacotherapy for secondary prevention of acute coronary
syndrome (ACS) is long-term treatment with a combination of four therapeutic classes: beta …

Background: Postdischarge use of evidence-based drug therapies has been proposed as a
measure of quality of care for myocardial infarction patients. We examined trends in the use …

BACKGROUND: There are limited data on the recent trend in the use of optimal evidence-
based medical therapies after acute coronary syndromes (ACSs). We sought to evaluate (1) …

Background It is not well-known to what extent evidence-based medications, such as β-
blockers, hypolipidemic medications, and angiotensin-converting enzyme inhibitors, are …

PURPOSE: To determine the rates of patient adherence to key evidence-based therapies at
6 months after hospital discharge for an acute coronary syndrome. METHODS: In this …

Objective To ascertain the use of secondary prevention medications and cardiac
rehabilitation after an acute coronary syndrome (ACS) and the impact on 2-year outcomes …

BACKGROUND: Coronary heart disease has emerged as a leading cause of death in
China. Although there is strong evidence for the use of antiplatelet, blood pressure …

Background: There is evidence that several classes of drugs are beneficial for secondary
prevention in patients with coronary artery disease. Objective: To compare the use of …

Guidelines for post–myocardial infarction (MI) management emphasize treatment with
statins, β blockers (BBs), and angiotensin-converting enzyme inhibitors (ACEIs) or …